Kolexia
Aleba Albert Oncologie médicale
Aleba Albert
Oncologie médicale
Centre Hospitalier de Niort
Niort, France
33 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du rectum Métastase tumorale Paresthésie Fatigue Tumeurs du côlon Hémopathies Tumeurs du foie Adénocarcinome Maladies gastro-intestinales

Collaborateurs

Voir plus
Bouamama Imane
Bouamama Imane
Centre Hospitalier de Niort, Niort, France
Pariente Francis
Pariente Francis
Centre Hospitalier de Niort, Niort, France
Pusniak Benoit
Pusniak Benoit
Cabinet libéral, Niort, France
Lecomte Thierry
Lecomte Thierry
Hôpital Trousseau Chambray lès Tours, Chambray-lès-Tours, France

Industries

Voir plus
Lilly
4 collaboration(s)
Dernière en 2023
MSD
3 collaboration(s)
Dernière en 2023
Novartis
2 collaboration(s)
Dernière en 2020
GSK
2 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
629P First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
The place of the relative at the time of the announcement of cancer progression: BABEL - a mixed-methods study.
Palliative & supportive care   26 juin 2023
First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis: Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis
Essai Clinique (Fédération Francophone de Cancérologie Digestive)   27 mars 2020
Surgical management of Low-Grade Serous Carcinoma of the ovary: Results of a multicenter study from The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO)
European journal of obstetrics, gynecology, and reproductive biology   01 mars 2019
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
European journal of cancer (Oxford, England : 1990)   18 octobre 2018
PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial).
2018 ASCO Annual Meeting I   01 juin 2018
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial
Abstract Book of the 42nd ESMO Congress (ESMO 2017) 8-12 September 2017, Madrid, Spain   01 septembre 2017
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Results of the FFCD 1102 phase II trial.
2016 ASCO Annual Meeting I   20 mai 2016
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
Annals of oncology : official journal of the European Society for Medical Oncology   25 juin 2015
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}